Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...
AnaptysBio, Inc. announced positive Phase 2b trial results for its lead drug, rosnilimab, which targets PD-1+ T cells for rheumatoid arthritis (RA), and will present updated data in June 2025. Initial ...
X4 Pharmaceuticals announced the acceptance of two abstracts for presentation at the upcoming European Hematology Association Congress regarding the positive results from their Phase 2 trial of ...
The last time I spoke about Tectonic Therapeutic, Inc. (TECX), it was in a Seeking Alpha article entitled "Tectonic: Expansion OF TX45 Candidate Possible After Positive Interim Data." In the article, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results